Majority control over cognitive health platform Happyneuron shifted to Raise Impact in new acquisition deal
In a significant move for the healthcare industry, Raise Impact, an impact investment fund, has invested a majority stake in Happyneuron, a French-based online platform specialising in cognitive health assessment and rehabilitation.
Happyneuron's platform, currently available in Luxembourg, Belgium, Switzerland, and North America, aims to expand further in these markets, though specific details about the markets and timelines for this expansion remain undisclosed. The platform offers 40 science-based digital modules designed by medical professionals, targeting key cognitive functions such as hearing, language, neurological impairments, and mathematical cognition.
The platform is particularly beneficial for diagnosing and treating 'dys' disorders like dyslexia, dyspraxia, or dysphasia, where individuals may wait up to a year to be seen by a professional. Happyneuron's tools have been adopted by hospitals and healthcare professionals, including neuropsychologists and clinical psychologists, and have more than 10,000 speech therapists as subscribed users.
The investment by Raise Impact will be used to grow Happyneuron's client base of healthcare practitioners, as well as to explore new fields of therapy, potentially through external growth. Raise Group will also help Happyneuron develop a structured approach to measure and manage its impact on improving patient care.
Happyneuron's solutions are backed by extensive research and publications, ensuring that medical professionals can interpret results accurately and craft effective care plans. The platform generates 70% of its revenue from subscriptions to its platform, demonstrating a resilient business model with stable levels of user retention.
Raise Impact focuses on taking active minority and majority controlling shares in European small and mid-cap growth companies, with ticket sizes ranging from €10m to €30m. The fund targets mission-driven companies that respond to challenges relating to energy transition, agricultural transition, circular economy, and social inclusion.
Bedrossian, a representative from Raise Impact, mentioned the possibility of acquisitions for Happyneuron in the future. France, Happyneuron's largest market, faces challenges in diagnosing many cognitive disorders due to high demand and limited availability. With Happyneuron's digital, scientifically grounded tool, healthcare professionals can diagnose disorders more precisely and efficiently, ensuring better patient outcomes, particularly during critical developmental periods like schooling.
- Raise Impact's investment in Happyneuron signals a broader shift towards development finance in the health-and-wellness sector, specifically focusing on cognitive health.
- The energy transition and agricultural transition are among the challenges that Raise Impact aims to address through its impact investment strategy, while also considering companies working on the circular economy and social inclusion.
- The fitness-and-exercise industry could potentially benefit from a similar approach to measurement and management of social impact, ensuring that businesses in this sector can demonstrate their positive impact on mental health and overall well-being.
- With science at its core, Happyneuron's platform offers a unique solution for those suffering from 'dys' disorders, bridging the gap between diagnosis and treatment that often results in lengthy waiting periods for professional help.
- As more businesses adopt digital tools to enhance their services in various sectors, including finance, business, and technology, the need for rigorous research and accurate interpretation of results becomes increasingly important.
- The growing adoption of digital health tools, such as Happyneuron's platform, can help address mental-health concerns, particularly during critical developmental periods like schooling, by ensuring faster, more precise diagnoses and treatments.
